Showing 2211-2220 of 5789 results for "".
- FDA Approves BMS' Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-bms-sotyktu-for-plaque-psoriasis/2461341/The FDA has approved Bristol Myers Squibb Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recom
- Daxxify from Revance Gets FDA Greenlighthttps://practicaldermatology.com/news/daxxify-from-revance-gets-fda-greenlight/2461331/Daxxify™ (DaxibotulinumtoxinA-lanm) from Revance is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. Daxxify is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum
- Boehringer Ingelheim's Spevigo Is first Treatment FDA-Approved for GPPhttps://practicaldermatology.com/news/boehringer-ingelheims-spevigo-is-first-treatment-fda-approved-for-gpp/2461327/FDA has approved Spevigo (spesolimab) from Boehringer Ingelheim as the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spevigo is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signali
- FDA Clears LASEROPTEK's HELIOS IV-785 for Aesthetic and Medical Dermatology Usehttps://practicaldermatology.com/news/fda-clears-laseropteks-helios-iv-785-for-aesthetic-and-medical-dermatology-use/2461326/The U.S. Food and Drug Administration has granted 510(k) clearance to LASEROPTEK Co., Ltd.’s HELIOS IV-785 laser system for aesthetic and medical dermatology applications. HELIOS IV-785's novel and synergistic combination of 785nm picosecond photoacoustic effect and 1064 &
- FDA Nod for Revelle Aesthetics, Inc's Avéli for Long-Term Reduction in Cellulitehttps://practicaldermatology.com/news/fda-nod-for-revelle-aesthetics-incs-aveli-for-long-term-reduction-in-cellulite/2461325/Revelle Aesthetics, Inc. scored an extended FDA clearance for Avéli. Avéli is now indicated for long-term reduction in the appearance of cellulite in the buttocks and thigh areas of adult females, demonstrating benefits through one year. "For far too l
- Study: Colorescience Total Eye Firm & Repair Cream Improves Appearance of Overall Periorbital Areahttps://practicaldermatology.com/news/study-colorescience-total-eye-firm-repair-cream-improves-appearance-of-overall-periorbital-area/2461316/Colorescience Total Eye Firm & Repair Cream improves periorbital wrinkles, dryness, laxity and dark circles, according to a study in the Journal of Cosmetic Dermatology. Results of the clinical study
- First Patient Dosed in Phase 1b/2 Trial of Dermaliq Therapeutics's DLQ02 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-1b2-trial-of-dermaliq-therapeuticss-dlq02-for-pso/2461310/The first patient has been dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor, Dermaliq Therapeutics, Inc. reports. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaqu
- Amorepacific Introduces the World's First Chip-less Wireless Electronic Skin Enabled by Semiconductorshttps://practicaldermatology.com/news/amorepacific-introduces-the-worlds-first-chip-less-wireless-electronic-skin-enabled-by-semiconductors/2461309/Amorepacific has developed the world's first chip-less wireless wearable electronic skin (e-skin) that is sweatproof and can continuously monitor skin changes over long periods of time. The result follows four years of joint research between Professor Professor&
- Rodan + Fields Gives Back: Company Announces More Donations from Youth Empowerment Fundhttps://practicaldermatology.com/news/rodan-fields-gives-back-company-announces-more-donations-from-youth-empowerment-fund/2461300/Rodan + Fields has announced the second round of donations from the Youth Empowerment Fund through their support of the Prescription for Change project. Launched in August 2021, the Fund will invest a total of $5 Million over three years to empower young people to l
- FDA Cracks Down on Three Companies for Selling Unapproved New Drugs for Mole and Skin Tag Removalhttps://practicaldermatology.com/news/fda-cracks-down-on-three-companies-for-selling-unapproved-new-drugs-for-mole-and-skin-tag-removal/2461294/The U.S. Food and Drug Administration issued three warning letters to three companies, including Amazon, for selling unapproved products for removing moles and skin tags, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). There are no FDA-appr